Century Therapeutics has been granted a patent for a universal chimeric antigen receptor system with adaptable receptor specificity. The system includes immune effector cells and soluble polypeptides for treating diseases. GlobalData’s report on Century Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Century Therapeutics Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Century Therapeutics, CAR-T cell based therapies was a key innovation area identified from patents. Century Therapeutics's grant share as of February 2024 was 4%. Grant share is based on the ratio of number of grants to total number of patents.

Universal chimeric antigen receptor system with adaptable receptor specificity

Source: United States Patent and Trademark Office (USPTO). Credit: Century Therapeutics Inc

A recently granted patent (Publication Number: US11883432B2) discloses a universal chimeric antigen receptor system with an adaptable receptor specificity component (arCAR). The system involves an immune effector cell with a chimeric antigen receptor and a soluble polypeptide with an antigen-binding domain that binds to a target cell's antigen. The immune effector cell can be derived from an induced pluripotent stem cell (iPSC), such as a T cell or NK cell.

Furthermore, the patent claims cover a method for treating diseases in a subject by administering the immune effector cell and the soluble polypeptide. The immune effector cell can be various types, including T cells, Natural Killer (NK) cells, or dendritic cells, derived from iPSCs. The method is particularly useful for treating cancers like glioblastoma, ovarian cancer, and hematologic malignancies, as well as autoimmune diseases. The immune effector cell can also be an allogeneic cell, providing a versatile approach to disease treatment.

To know more about GlobalData’s detailed insights on Century Therapeutics, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies